Cellectis (CLLS) EBIT Margin (2016 - 2023)
Historic EBIT Margin for Cellectis (CLLS) over the last 9 years, with Q3 2023 value amounting to 13336.13%.
- Cellectis' EBIT Margin rose 22941600.0% to 13336.13% in Q3 2023 from the same period last year, while for Sep 2023 it was 444.85%, marking a year-over-year increase of 2380500.0%. This contributed to the annual value of 348.56% for FY2022, which is 2586200.0% down from last year.
- According to the latest figures from Q3 2023, Cellectis' EBIT Margin is 13336.13%, which was up 22941600.0% from 13270.22% recorded in Q2 2023.
- Cellectis' EBIT Margin's 5-year high stood at 28.75% during Q1 2020, with a 5-year trough of 16856.83% in Q1 2023.
- Moreover, its 5-year median value for EBIT Margin was 870.34% (2019), whereas its average is 3805.73%.
- In the last 5 years, Cellectis' EBIT Margin soared by 28762700bps in 2019 and then tumbled by -151205600bps in 2022.
- Over the past 5 years, Cellectis' EBIT Margin (Quarter) stood at 870.34% in 2019, then soared by 67bps to 286.94% in 2020, then soared by 74bps to 74.8% in 2021, then skyrocketed by 53bps to 35.32% in 2022, then tumbled by -37656bps to 13336.13% in 2023.
- Its last three reported values are 13336.13% in Q3 2023, 13270.22% for Q2 2023, and 16856.83% during Q1 2023.